Lung Diseases Cies Search Engine [selected websites]

Showing posts with label Merck. Show all posts
Showing posts with label Merck. Show all posts

Jun 24, 2010

FDA Approves Merck's DULERA® Inhalation Aerosol for the Treatment of Asthma in Patients 12 Years of Age and Older

Merck June 24, 2010 – Merck announced that the U.S. Food and Drug Administration (FDA) has approved DULERA (mometasone furoate and formoterol fumarate dihydrate) Inhalation Aerosol, a new fixed-dose combination asthma treatment for patients 12 years of age and older. DULERA is not indicated for the relief of acute bronchospasm. DULERA combines an inhaled corticosteroid (mometasone furoate) with a long-acting beta2-agonist (formoterol fumarate). The approval of DULERA is based, in part, on Phase III studies that evaluated the safety and efficacy of DULERA in patients 12 years of age and older with persistent asthma.

"Despite the advances made in the treatment of asthma in recent years, many patients may still not be well-controlled on their current therapies,”... Merck's Press Release -

Jul 21, 2008

Schering-Plough and Merck & Co. : Withdrawal of Loratadine/Montelukast NDA and Termination of Respiratory Joint Venture

June 27, 2008 - Schering-Plough Corp. (NYSE: SGP) and Merck & Co., Inc. (NYSE: MRK) announce the withdrawal of the New Drug Application (NDA) for the loratadine/montelukast combination tablet.
The companies also terminated the Schering-Plough/Merck Pharmaceuticals respiratory joint venture, which was formed in May 2000 to develop and market a fixed-combination product that would combine loratadine and montelukast.
This action has no impact on the business of the Merck/Schering-Plough cholesterol joint venture... Merck's Press Release - Schering-Plough's Press Release -

May 19, 2008

GE HEALTHCARE & Merck : GLOBAL MOLECULAR DIAGNOSTIC AGREEMENT TO ADVANCE RESPIRATORY DRUG DEVELOPMENT

May 05, 2008 - - GE Healthcare, a subsidiary of the General Electric Company (NYSE:GE) announced today that it has signed a non-exclusive agreement with Merck & Co., Inc. to share technology on imaging of the lungs that may help to advance respiratory treatment development.

Under terms of the agreement, Merck will be granted access to Spin Signal TechnologyTM (SST) utilizing hyperpolarized Xenon 129 gas, a molecular imaging agent that is under investigation by GE Healthcare to provide high speed, quantitative imaging of the lung using Magnetic Resonance Imaging (MRI). GE Healthcare originally licensed this technology from Princeton University... GE Healthcare's Press Release -

Mar 27, 2008

Merck Statement on the FDA Early Communication of an Ongoing Safety Review of Montelukast (SINGULAIR™)

March 27, 2008 - Merck & Co., Inc. issued the following statement in response to the FDA Early Communication of an Ongoing Safety Review of Montelukast (SINGULAIR™) that was posted today on the FDA website.

SINGULAIR has been marketed in the US for 10 years and millions of patients have been prescribed SINGULAIR in the US and around the world. Merck voluntarily updated the worldwide product label for SINGULAIR in October 2007 to include "suicidal thinking and behavior" and included similar changes to the patient product information. These actions were based on a very limited number of post-marketing adverse event reports that Merck has received. Since that time, Merck has worked with the U.S. Food and Drug Administration to provide further clarity in the product label as well as to further communicate this information to physicians.

Information from post-marketing reports is incorporated by Merck into the product label and patient product information as appropriate to help inform healthcare practitioners and patients. The fact that an adverse event has been reported to Merck and to regulatory agencies does not reflect a conclusion that the post-marketing event is caused by SINGULAIR. In general, a post-marketing adverse event may be caused by underlying disease, genetic condition, the medication, concomitant medications or background event that may occur in any population... Merck's Press Release -

Mar 25, 2008

MicroDose Technologies : Global License to Merck & Co., Inc., for Use of the MicroDose Inhaler with Merck's Proprietary Products

March 3, 2008 - MicroDose TechnologiesInc. (MicroDose) announced that it has entered into a global license agreement with Merck & Co., Inc., through an affiliate, for use of MicroDose's proprietary dry powder inhaler (DPI) with Merck compounds. This agreement follows the successful completion of an exploratory study evaluating the MicroDose DPI technology.... [PDF]MicroDose Technologies' Press Release -